| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2026 | 26 | 0.930 |
Why?
|
| Mycophenolic Acid | 1 | 2026 | 61 | 0.930 |
Why?
|
| Cytodiagnosis | 3 | 2013 | 20 | 0.880 |
Why?
|
| Influenza, Human | 3 | 2021 | 700 | 0.870 |
Why?
|
| Rituximab | 1 | 2026 | 172 | 0.860 |
Why?
|
| Immunologic Factors | 1 | 2026 | 188 | 0.850 |
Why?
|
| Influenza B virus | 3 | 2021 | 102 | 0.820 |
Why?
|
| Pathology, Surgical | 2 | 2013 | 16 | 0.790 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2021 | 145 | 0.770 |
Why?
|
| Influenza A virus | 2 | 2021 | 143 | 0.740 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 284 | 0.730 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2020 | 29 | 0.700 |
Why?
|
| Immunosuppressive Agents | 1 | 2026 | 658 | 0.700 |
Why?
|
| Papillomaviridae | 2 | 2013 | 178 | 0.700 |
Why?
|
| ErbB Receptors | 2 | 2013 | 294 | 0.700 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2020 | 5 | 0.660 |
Why?
|
| False Positive Reactions | 1 | 2021 | 143 | 0.660 |
Why?
|
| Disease Notification | 1 | 2020 | 9 | 0.650 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 173 | 0.640 |
Why?
|
| Virology | 2 | 2017 | 31 | 0.640 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2020 | 108 | 0.630 |
Why?
|
| Antigens, Viral | 1 | 2021 | 392 | 0.600 |
Why?
|
| Pharyngitis | 1 | 2019 | 34 | 0.580 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 170 | 0.580 |
Why?
|
| Streptococcus pyogenes | 1 | 2019 | 84 | 0.560 |
Why?
|
| Papillomavirus Infections | 2 | 2013 | 384 | 0.550 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2025 | 280 | 0.540 |
Why?
|
| Polymerase Chain Reaction | 2 | 2019 | 1457 | 0.530 |
Why?
|
| Sensitivity and Specificity | 8 | 2021 | 2121 | 0.520 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 17 | 0.520 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 293 | 0.520 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 314 | 0.510 |
Why?
|
| Osteomyelitis | 1 | 2019 | 209 | 0.510 |
Why?
|
| Pandemics | 3 | 2021 | 1154 | 0.510 |
Why?
|
| Vaccines | 1 | 2021 | 380 | 0.500 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 252 | 0.480 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 208 | 0.480 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 987 | 0.470 |
Why?
|
| Liposarcoma | 1 | 2014 | 23 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2014 | 79 | 0.420 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2017 | 385 | 0.390 |
Why?
|
| Mutation | 5 | 2020 | 6140 | 0.390 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 1535 | 0.380 |
Why?
|
| Algorithms | 1 | 2019 | 1680 | 0.380 |
Why?
|
| Vaginal Smears | 1 | 2012 | 47 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 2 | 2026 | 2551 | 0.360 |
Why?
|
| DNA, Viral | 1 | 2013 | 451 | 0.350 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2021 | 97 | 0.310 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6774 | 0.310 |
Why?
|
| Humans | 33 | 2026 | 130573 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 636 | 0.280 |
Why?
|
| Texas | 3 | 2021 | 3606 | 0.280 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 690 | 0.270 |
Why?
|
| Female | 22 | 2026 | 70513 | 0.260 |
Why?
|
| Prevalence | 4 | 2021 | 2684 | 0.250 |
Why?
|
| Agammaglobulinemia | 1 | 2006 | 43 | 0.240 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2006 | 31 | 0.240 |
Why?
|
| Gram-Negative Bacteria | 1 | 2026 | 74 | 0.230 |
Why?
|
| Retinitis Pigmentosa | 1 | 2006 | 89 | 0.230 |
Why?
|
| Vagina | 4 | 2021 | 207 | 0.230 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2026 | 94 | 0.230 |
Why?
|
| Young Adult | 6 | 2020 | 9991 | 0.220 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 527 | 0.220 |
Why?
|
| Surgical Mesh | 3 | 2009 | 64 | 0.210 |
Why?
|
| Testis | 1 | 2006 | 399 | 0.210 |
Why?
|
| Prospective Studies | 6 | 2026 | 6475 | 0.210 |
Why?
|
| Genotype | 3 | 2015 | 2609 | 0.200 |
Why?
|
| Adult | 11 | 2022 | 31204 | 0.200 |
Why?
|
| Drug Therapy, Combination | 1 | 2026 | 1165 | 0.180 |
Why?
|
| Seasons | 2 | 2021 | 334 | 0.180 |
Why?
|
| Bacteremia | 1 | 2026 | 426 | 0.180 |
Why?
|
| Trichomonas vaginalis | 1 | 2021 | 10 | 0.180 |
Why?
|
| Trichomonas Vaginitis | 1 | 2021 | 14 | 0.180 |
Why?
|
| Middle Aged | 8 | 2022 | 28450 | 0.170 |
Why?
|
| Male | 15 | 2022 | 64560 | 0.170 |
Why?
|
| Device Approval | 1 | 2021 | 12 | 0.170 |
Why?
|
| Polypropylenes | 3 | 2009 | 15 | 0.170 |
Why?
|
| Mycoplasma genitalium | 1 | 2020 | 4 | 0.160 |
Why?
|
| Mycoplasma Infections | 1 | 2020 | 10 | 0.160 |
Why?
|
| Nasopharynx | 2 | 2019 | 86 | 0.160 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2012 | 103 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 125 | 0.160 |
Why?
|
| SMARCB1 Protein | 1 | 2020 | 42 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 190 | 0.160 |
Why?
|
| Aged | 5 | 2020 | 20926 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 69 | 0.160 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 94 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 289 | 0.150 |
Why?
|
| Emergencies | 1 | 2021 | 178 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 240 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2013 | 260 | 0.150 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 53 | 0.150 |
Why?
|
| Breast | 1 | 2020 | 216 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 112 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 783 | 0.140 |
Why?
|
| Pathology | 1 | 2018 | 27 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2019 | 83 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2020 | 315 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 115 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2019 | 161 | 0.130 |
Why?
|
| Viruses | 1 | 2019 | 117 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 265 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 2932 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Child | 4 | 2026 | 26148 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 498 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 1150 | 0.120 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2017 | 153 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 311 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2020 | 357 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2018 | 680 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1232 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 756 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 682 | 0.110 |
Why?
|
| Bacteria | 1 | 2019 | 538 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2017 | 561 | 0.110 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 32 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 1165 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1892 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2019 | 752 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2014 | 41 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2014 | 225 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 552 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2019 | 14987 | 0.100 |
Why?
|
| beta-Globins | 1 | 2013 | 9 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1791 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 73 | 0.100 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 42 | 0.100 |
Why?
|
| Caliciviridae Infections | 1 | 2015 | 286 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 32 | 0.100 |
Why?
|
| Monoamine Oxidase | 1 | 2012 | 18 | 0.090 |
Why?
|
| Choledochal Cyst | 1 | 2012 | 9 | 0.090 |
Why?
|
| DNA Contamination | 1 | 2012 | 1 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 752 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2019 | 783 | 0.090 |
Why?
|
| Norovirus | 1 | 2015 | 284 | 0.090 |
Why?
|
| Equipment Contamination | 1 | 2012 | 40 | 0.090 |
Why?
|
| Feces | 1 | 2015 | 722 | 0.090 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2011 | 10 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 125 | 0.080 |
Why?
|
| Adolescent | 3 | 2019 | 20774 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 788 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 2012 | 129 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1314 | 0.080 |
Why?
|
| Genomics | 1 | 2018 | 1622 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2012 | 414 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 48 | 0.080 |
Why?
|
| Dermis | 1 | 2009 | 27 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 1592 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2017 | 2468 | 0.070 |
Why?
|
| Cell Size | 1 | 2009 | 79 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1603 | 0.070 |
Why?
|
| Macrophages | 2 | 2025 | 652 | 0.070 |
Why?
|
| Abdomen | 1 | 2009 | 129 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2008 | 30 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 120 | 0.070 |
Why?
|
| Infant | 3 | 2021 | 13306 | 0.070 |
Why?
|
| Foreign-Body Reaction | 1 | 2008 | 16 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 1214 | 0.060 |
Why?
|
| Bioprosthesis | 1 | 2008 | 112 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8553 | 0.060 |
Why?
|
| Collagen | 1 | 2008 | 284 | 0.060 |
Why?
|
| Oligospermia | 1 | 2006 | 65 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2009 | 595 | 0.060 |
Why?
|
| Sertoli Cells | 1 | 2006 | 74 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 3702 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17655 | 0.060 |
Why?
|
| Estrogens | 2 | 2023 | 432 | 0.060 |
Why?
|
| Anaphylatoxins | 1 | 2004 | 3 | 0.060 |
Why?
|
| Bradykinin | 1 | 2004 | 43 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 744 | 0.050 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2005 | 87 | 0.050 |
Why?
|
| Erythema | 1 | 2004 | 28 | 0.050 |
Why?
|
| Angioedema | 1 | 2004 | 21 | 0.050 |
Why?
|
| Rabbits | 3 | 2009 | 572 | 0.050 |
Why?
|
| Syndrome | 1 | 2006 | 1159 | 0.050 |
Why?
|
| Lymphoma | 1 | 2006 | 329 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2026 | 392 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2026 | 843 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2012 | 3712 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2023 | 57 | 0.050 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Calcifediol | 1 | 2022 | 13 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 151 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 114 | 0.040 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2021 | 128 | 0.040 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2021 | 19 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 239 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 35 | 0.040 |
Why?
|
| Nucleocapsid Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 45 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2021 | 1092 | 0.040 |
Why?
|
| Urogenital System | 1 | 2020 | 34 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 196 | 0.040 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2020 | 8 | 0.040 |
Why?
|
| Calreticulin | 1 | 2020 | 23 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 209 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 130 | 0.040 |
Why?
|
| Granulocytes | 1 | 2019 | 68 | 0.040 |
Why?
|
| Prognosis | 2 | 2021 | 4927 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 145 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 51 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 68 | 0.040 |
Why?
|
| Ovariectomy | 2 | 2009 | 159 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 4700 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 217 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 137 | 0.040 |
Why?
|
| Kidney | 1 | 2005 | 1283 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2019 | 296 | 0.030 |
Why?
|
| Transcriptome | 1 | 2025 | 1132 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 483 | 0.030 |
Why?
|
| Animals | 7 | 2019 | 33897 | 0.030 |
Why?
|
| Risk Factors | 1 | 2012 | 10993 | 0.030 |
Why?
|
| Epithelium | 2 | 2009 | 339 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 791 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 364 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2009 | 3114 | 0.030 |
Why?
|
| Models, Animal | 2 | 2009 | 457 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 1694 | 0.030 |
Why?
|
| Hypertension | 1 | 2005 | 1357 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1684 | 0.030 |
Why?
|
| Vaccination | 1 | 2021 | 1033 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1238 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 378 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1509 | 0.020 |
Why?
|
| Cell Movement | 1 | 2017 | 868 | 0.020 |
Why?
|
| Sp1 Transcription Factor | 1 | 2012 | 37 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 229 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 240 | 0.020 |
Why?
|
| Serotonin | 1 | 2012 | 211 | 0.020 |
Why?
|
| Dopamine | 1 | 2012 | 250 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2849 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 705 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 840 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2306 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 80 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 3413 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 64 | 0.020 |
Why?
|
| Proteome | 1 | 2011 | 288 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1213 | 0.020 |
Why?
|
| Biomarkers | 2 | 2011 | 3397 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4663 | 0.020 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2009 | 58 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 258 | 0.020 |
Why?
|
| Laparotomy | 1 | 2009 | 140 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 771 | 0.020 |
Why?
|
| Mice | 3 | 2012 | 18222 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 462 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 673 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 606 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2008 | 177 | 0.020 |
Why?
|
| Fibrosis | 1 | 2008 | 417 | 0.020 |
Why?
|
| United States | 1 | 2021 | 11820 | 0.010 |
Why?
|
| Desoxycorticosterone | 1 | 2005 | 11 | 0.010 |
Why?
|
| Swine | 1 | 2009 | 1187 | 0.010 |
Why?
|
| Nephritis | 1 | 2005 | 17 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3413 | 0.010 |
Why?
|
| Urine | 1 | 2005 | 90 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 91 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2005 | 90 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 122 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 72 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 112 | 0.010 |
Why?
|
| Proteinuria | 1 | 2005 | 106 | 0.010 |
Why?
|
| Albuminuria | 1 | 2005 | 105 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 2018 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 397 | 0.010 |
Why?
|
| Inflammation | 1 | 2009 | 1489 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 1342 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 3834 | 0.010 |
Why?
|